High fidelity cell culture process for AAV production demonstrates scalability, improved productivity and reduced partial and empty capsids

Authors

• Madhuresh Sumit, Sanofi, USAFollow
• Rachel Sun, Genomic Medicine Unit CMC, Sanofi, Waltham, MA, USA
• Bruno Figueroa, Genomic Medicine Unit CMC, Sanofi, Waltham, MA, USA
• Jeong Lee, Genomic Medicine Unit CMC, Sanofi, Waltham, MA, USA
• Ying Liu, Genomic Medicine Unit CMC, Sanofi, Waltham, MA, USA
• Adhvait Shah, Genomic Medicine Unit CMC, Sanofi, Waltham, MA, USA
• Daniel Furey, Genomic Medicine Unit CMC, Sanofi, Waltham, MA, USA
• Olivia Tsang, Genomic Medicine Unit CMC, Sanofi, Waltham, MA, USA
• David Diaz, Genomic Medicine Unit CMC, Sanofi, Waltham, MA, USA
• Nipun Goel, Genomic Medicine Unit CMC, Sanofi, Waltham, MA, USA

Conference Dates

February 1 – 5, 2026

Abstract

Please click Additional Files below to see the full abstract

Recommended Citation

Madhuresh Sumit, Rachel Sun, Bruno Figueroa, Jeong Lee, Ying Liu, Adhvait Shah, Daniel Furey, Olivia Tsang, David Diaz, and Nipun Goel, "High fidelity cell culture process for AAV production demonstrates scalability, improved productivity and reduced partial and empty capsids" in "Advancing Manufacture of Cell and Gene Therapies IX [2026]", John Moscariello, Neuvogen, USA Corinne Hoesli, McGill University, Canada Bruno Marques, Century Therapeutics, USA Eds, ECI Symposium Series, (2026). https://dc.engconfintl.org/cell_gene_therapies_ix/73